Ritchlin CT, et al. - Researchers evaluated bimekizumab, a monoclonal antibody that selectively neutralizes interleukin 17A (IL17A) and IL17F, in individuals with active psoriatic arthritis. Reseachers conducted a randomized, double-blind, placebo-controlled, dose-ranging phase 2b study at 41 sites in the Czech Republic, Germany, Hungary, Poland, Russia, and the USA. In this study, 308 individuals were screened, and 206 were randomly assigned: 42 to the placebo group, and 41 each to the four bimekizumab groups between Oct 27, 2016, and July 16, 2018. They randomized eligible individuals aged 18 years or older with active adult-onset psoriatic arthritis and symptoms for at least 6 months (1:1:1:1:1) to placebo, 16 mg bimekizumab, 160 mg bimekizumab, 160 mg bimekizumab with a one-off 320 mg loading dose, or 320 mg bimekizumab, which were administered as subcutaneous injections every 4 weeks for 12 weeks. Compared with placebo, bimekizumab doses of 16 mg and 160 mg (with or without a 320 mg loading dose) were correlated with significant improvements in ACR50, with an acceptable safety profile. In addition, the outcomes support phase 3 investigation of bimekizumab as a treatment for psoriatic arthritis.